Literature DB >> 29296904

Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH.

Anna Hayden1, Molly Lin1, Sujin Park1, Morris Pudek2, Marion Schneider3, Michael B Jordan4,5, Andre Mattman2, Luke Y C Chen1.   

Abstract

Serum soluble interleukin-2 receptor (sIL-2r) is an important disease marker in hemophagocytic lymphohistiocytosis (HLH), but there are no published data on its diagnostic value in adults. We conducted a single-center retrospective study of 78 consecutive adults who had sIL-2r measured for suspected HLH. Serum sIL-2r levels were measured by enzyme-linked immunosorbent assay (adult reference range, 241-846 U/mL). There were 38 patients with HLH and 40 with a non-HLH diagnosis (such as sepsis, liver disease, histiocyte disorders, autoimmune disease, leukemia, or lymphoma). The receiver operating characteristic curve demonstrated that sIL-2r is a good to excellent diagnostic test for adult HLH, with an area under the curve (AUC) of 0.90 (95% confidence interval, 0.83-0.97) compared with AUC 0.78 (95% confidence interval, 0.67-0.88) for ferritin. The optimal threshold for sIL-2r was 2515 U/mL (sensitivity, 100%; specificity, 72.5%). Although there was a large indeterminate range for sIL-2r, a level of 2400 U/mL or less was helpful for ruling out HLH (sensitivity, 100%), and more than 10 000 U/mL was helpful for ruling in HLH (specificity, 93%). Higher mean sIL-2r levels were seen in malignancy-associated HLH (20 241 U/mL) compared with infection-associated HLH and macrophage activation syndrome (9720 and 5008 U/mL, respectively; P < .05). Levels above 10 000 U/mL were not associated with worse prognosis in patients with HLH. Serum sIL-2r is a sensitive test for diagnosis of adult HLH, but is not as specific as previously reported in children. Additional studies enriched with patients without HLH who have conditions associated with T-cell activation, such as lymphoma and autoimmune lymphoproliferative syndrome, are needed.

Entities:  

Year:  2017        PMID: 29296904      PMCID: PMC5728644          DOI: 10.1182/bloodadvances.2017012310

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  18 in total

Review 1.  Modern management of children with haemophagocytic lymphohistiocytosis.

Authors:  Gritta E Janka; E M Schneider
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

3.  Marked hyperferritinemia does not predict for HLH in the adult population.

Authors:  Alison M Schram; Federico Campigotto; Ann Mullally; Annemarie Fogerty; Elena Massarotti; Donna Neuberg; Nancy Berliner
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

4.  Conditions associated with extreme hyperferritinaemia (>3000 μg/L) in adults.

Authors:  A J Wormsbecker; D D Sweet; S L Mann; S Y Wang; M R Pudek; L Y C Chen
Journal:  Intern Med J       Date:  2015-08       Impact factor: 2.048

Review 5.  Similar but not the same: Differential diagnosis of HLH and sepsis.

Authors:  Rafał Machowicz; Gritta Janka; Wieslaw Wiktor-Jedrzejczak
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-23       Impact factor: 6.312

Review 6.  The soluble interleukin-2 receptor: biology, function, and clinical application.

Authors:  L A Rubin; D L Nelson
Journal:  Ann Intern Med       Date:  1990-10-15       Impact factor: 25.391

7.  The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

Authors:  Jack Bleesing; Anne Prada; David M Siegel; Joyce Villanueva; Judyann Olson; Norman T Ilowite; Hermine I Brunner; Thomas Griffin; Thomas B Graham; David D Sherry; Murray H Passo; Athimalaipet V Ramanan; Alexandra Filipovich; Alexei A Grom
Journal:  Arthritis Rheum       Date:  2007-03

Review 8.  Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis.

Authors:  Kai Lehmberg; Stephan Ehl
Journal:  Br J Haematol       Date:  2012-12-04       Impact factor: 6.998

9.  Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis.

Authors:  Snjezana Rothkrantz-Kos; Marja P van Dieijen-Visser; Paul G H Mulder; Marjolein Drent
Journal:  Clin Chem       Date:  2003-09       Impact factor: 8.327

10.  A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome.

Authors:  Takahiro Tsuji; Taichi Hirano; Hiroshi Yamasaki; Mayumi Tsuji; Hiroyuki Tsuda
Journal:  Ann Hematol       Date:  2013-10-25       Impact factor: 3.673

View more
  39 in total

1.  Tuberculosis-associated hemophagocytic lymphohistiocytosis with subsequent unmasking cryptococcal immune reconstitution inflammatory syndrome (IRIS) in an HIV-negative man.

Authors:  Hilte F Geerdes-Fenge; Micha Löbermann; Christoph J Hemmer; Orsolya Benedek; Emil C Reisinger
Journal:  Infection       Date:  2018-09-26       Impact factor: 3.553

Review 2.  Pediatric hemophagocytic lymphohistiocytosis.

Authors:  Scott W Canna; Rebecca A Marsh
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

3.  Enterovirus-associated hemophagocytic lymphohistiocytosis with multiorgan failure.

Authors:  Azaan Ramani; Sivakumar Sudhakaran; Robert S Rahimi; Joseph Guileyardo; Uriel S Sandkovsky
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-03-06

Review 4.  Haemophagocytic lymphohistiocytosis in pregnancy.

Authors:  Harold Wilson-Morkeh; Charlotte Frise; Taryn Youngstein
Journal:  Obstet Med       Date:  2021-09-26

5.  An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis.

Authors:  Adi Zoref-Lorenz; Jun Murakami; Liron Hofstetter; Swaminathan Iyer; Ahmad S Alotaibi; Shehab Fareed Mohamed; Peter G Miller; Elad Guber; Shiri Weinstein; Joanne Yacobovich; Sarah Nikiforow; Benjamin L Ebert; Adam Lane; Oren Pasvolsky; Pia Raanani; Arnon Nagler; Nancy Berliner; Naval Daver; Martin Ellis; Michael B Jordan
Journal:  Blood       Date:  2022-02-17       Impact factor: 25.476

Review 6.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

7.  Analysis of the occurrence of hemophagocytic lymphohistiocytosis (HLH) features in patients with sepsis: a prospective study.

Authors:  Dominik Bursa; Agnieszka Bednarska; Andrzej Pihowicz; Marcin Paciorek; Andrzej Horban
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

Review 8.  Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).

Authors:  Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2019-07-24       Impact factor: 3.167

9.  Systems controls are needed to reduce mistaken tests for hemophagocytic lymphohistiocytosis, results of a prospective quality-improvement cohort study.

Authors:  Salahuddin Safi; Satish Shanbhag; Bryan C Hambley; Samuel A Merrill
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

10.  A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis.

Authors:  Samuel A Merrill; Rakhi Naik; Michael B Streiff; Satish Shanbhag; Sophie Lanzkron; Evan M Braunstein; Alison M Moliterno; Robert A Brodsky
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.